Mercedes García-Gasalla

Dr. Mercedes García-Gasalla

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
IVIsabel Mir Viladrich
Isabel Mir Viladrich
ETEsteban Daudén Tello
Esteban Daudén Tello
GSGuillermo Solano-López
Guillermo Solano-López
FLFrancisco Javier López Longo
Francisco Javier López Longo
CSCarlos Taxonera Samso
Carlos Taxonera Samso
JGJosé Maria García García
José Maria García García


15 November 2004 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ABAlejandra Biglia
Alejandra Biglia
JBJose L. Blanco
Jose L. Blanco
EMEsteban Martínez
Esteban Martínez
PDPere Domingo
Pere Domingo
RCRoser Casamitjana
Roser Casamitjana
JGJose M. Gatell
Jose M. Gatell
Background. The prevalence, risk factors, and potential hormonal abnormalities associated with gynecomastia in a cohort of HIV-infected men are poorl

14 May 2018 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
ILInés Losada
Inés Losada
JGJuan González‐Moreno
Juan González‐Moreno
NRNuria Roda
Nuria Roda
LVLola Ventayol
Lola Ventayol
YBYolanda Borjas
Yolanda Borjas
APAntoni Payeras
Antoni Payeras

18 August 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLaura Muñoz
Laura Muñoz
Miguel SantinMiguel Santin
Miguel Santin
FAFernando Alcaide
Fernando Alcaide
MRMaria Jesús Ruíz-Serrano
Maria Jesús Ruíz-Serrano
PGPaloma Gijón
Paloma Gijón
RCRaquel Carrillo
Raquel Carrillo
Screening strategies based on interferon-γ release assays in tuberculosis contact tracing may reduce the need for preventive therapy without increasing subsequent active disease. We conducted an open-label, randomized trial to test the noninferiority of a 2-step strategy with the tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-GIT) as a confirmatory test (the TST/QFT arm) to the standard TST-alone strategy (TST arm) for targeting preventive therapy in household contacts of patients with tuberculosis. Participants were followed for 24 months after randomization. The primary endpoint was the development of tuberculosis, with a noninferiority margin of 1.5 percentage points. A total of 871 contacts were randomized. Four contacts in the TST arm and 2 in the TST/QFT arm developed tuberculosis. In the modified intention-to-treat analysis, this accounted for 0.99% in the TST arm and 0.51% in the TST/QFT arm (−0.48% difference; 97.5% confidence interval [CI], −1.86% to 0.90%); in the per-protocol analysis, the corresponding rates were 1.67% and 0.82% in the TST and TST/QFT arms, respectively (−0.85% difference; 97.5% CI, −3.14% to 1.43%). Of the 792 contacts analyzed, 65.3% in the TST arm and 42.2% in the TST/QFT arm were diagnosed with tuberculosis infection (23.1% difference; 95% CI, 16.4% to 30.0%). In low-incidence settings, screening household contacts with the TST and using QFT-GIT as a confirmatory test is not inferior to TST-alone for preventing active tuberculosis, allowing a safe reduction of preventive treatments. NCT01223534.

29 March 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
MGMercedes García-Gasalla
Mercedes García-Gasalla
MBMaría Berman-Riu
María Berman-Riu
JPJaime Pons
Jaime Pons
ARAdrián Rodríguez
Adrián Rodríguez
AIAmanda Iglesias
Amanda Iglesias
JFJoana M. Ferrer
Joana M. Ferrer
Background: A better understanding of COVID-19 immunopathology is needed to identify the most vulnerable patients and improve treatment options.Objective: We aimed to identify immune system cell populations, cytokines, and inflammatory markers related to severity in COVID-19.Methods: 139 hospitalized patients with COVID-19−58 mild/moderate and 81 severe/critical—and 74 recovered patients were included in a prospective longitudinal study. Clinical data and blood samples were obtained on admission for laboratory markers, cytokines, and lymphocyte subsets study. In the recovered patients, lymphocyte subsets were analyzed 8–12 weeks after discharge.Results: A National Early Warning Score 2 >2 (OR:41.4; CI:10.38–167.0), ferritin >583 pg/mL (OR:16.3; CI: 3.88–69.9), neutrophil/lymphocyte ratio >3 (OR: 3.5; CI: 1.08–12.0), sIL-2rα (sCD25) >512 pg/mL (OR: 3.3; CI: 1.48–7.9), IL-1Ra >94 pg/mL (OR: 3.2; IC: 1.4–7.3), and IL-18 >125 pg/mL (OR: 2.4; CI: 1.1–5.0) were associated with severe/critical COVID-19 in the multivariate models used. Lower absolute values of CD3, CD4, CD8, and CD19 lymphocytes together with higher frequencies of NK cells, a CD4 and CD8 activated (CD38+HLA-DR+) memory T cell and effector memory CD45RA+ (EMRA) phenotype, and lower T regulatory cell frequencies were found in severe/critical patients relative to mild/moderate and recovered COVID-19 patients. A significant reduction in Th1, Tfh1, and Tc1 with higher Th2, Tfh2, Tc2, and plasma cell frequencies was found in the most severe cases.Conclusion: A characteristic hyperinflammatory state with significantly elevated neutrophil/lymphocyte ratio and ferritin, IL-1Ra, sIL-2rα, and IL-18 levels together with a “low T1 lymphocyte signature” was found in severe/critical COVID-19 patients.